Drugs / BIWH 3
BIWH 3
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02249117 | Jun → Aug 2003 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02215824 | Oct 2002 → Oct 2003 | peripheral arterial disease | Boehringer Ingelheim | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIWH 3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02249117 ↗ |
| Known as | pyro-Glu-rhMCP-1 | “The primary aim of this trial was to investigate the safety of a 6 hour intraarterial infusion of BIWH 3 (pyro-Glu-rhMCP-1) in patients with severe peripheral arterial...” NCT02215824 ↗ |
| Known as | recombinant human pyro-Glu MCP-1 | “recombinant human pyro-Glu MCP-1 (BIWH 3)” NCT02249117 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human pyro-Glu MCP-1 (BIWH 3)” NCT02249117 ↗ |
| Route | Other | “6 hour intraarterial infusion of BIWH 3” NCT02215824 ↗ |